<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9413958</article-id><article-id pub-id-type="pmc">2228192</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Formelli</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cavadini</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mascheroni</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Belli</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cascinelli</surname><given-names>N.</given-names></name></contrib></contrib-group><aff>Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>76</volume><issue>12</issue><fpage>1655</fpage><lpage>1660</lpage><abstract><p>The pharmacokinetics of 13-cis-retinoic acid (13cisRA) and its effects on retinol plasma levels were investigated after the first and the last doses in melanoma patients, who participated in a study run to assess tolerance over a long period of a treatment schedule of 13cisRA associated with recombinant interferon alpha2a (rIFN-alpha2a). Melanoma patients with regional node metastases after radical surgery were randomized to be treated for 3 months with rIFN-alpha2a, 3 x 10(6) IU s.c. every other day, associated with oral 13cisRA at doses of 20 mg day(-1) (five patients) or 40 mg every other day (seven patients). Maximum 13cisRA blood concentrations usually occurred 4 h after drug administration, with average values of 406 and 633 ng ml(-1) (i.e. 1.3 and 2.1 microM) after the 20 and 40 mg dose respectively. The average half-life (t(1/2)) was approximately 30 h. The maximum concentration, the t(1/2) and the area under the concentration-time curves from 0 to 48 h (AUC(0-48)) of 13cisRA did not change after multiple dosing, whereas the AUC(0-48) of its major blood metabolite, 4-oxo-13-cis-retinoic acid, increased. Immediately after 13cisRA treatment, retinol plasma levels started to decline and they reached the lowest values (approximately 20% reduction) shortly after the time of maximum 13cisRA concentrations (i.e. 4-12 h after drug intake). Afterwards, values returned to baseline. The amount of retinol reduction in time was correlated with 13cisRA maximum concentrations.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00176-0121.tif" xlink:title="scanned-page" xlink:role="1655" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00176-0122.tif" xlink:title="scanned-page" xlink:role="1656" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00176-0123.tif" xlink:title="scanned-page" xlink:role="1657" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00176-0124.tif" xlink:title="scanned-page" xlink:role="1658" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00176-0125.tif" xlink:title="scanned-page" xlink:role="1659" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00176-0126.tif" xlink:title="scanned-page" xlink:role="1660" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

